Sign in
Taking peopleNo phase

Efficacy of Anisodamine Hydrobromide Combined With Low-molecular-weight Heparin in the Treatment of Patients With Sepsis

Key facts

Who runs it
Chen Ying
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
782 people, planned
Started
25 Jan 2024
Planned end
Dec 2025
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Anisodamine hydrobromide combined with heparin
Record updated
21 May 2025

Who can take part

Age
18 years to 110 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (9)Hide the full registry criteria

Who can take part

  • Age greater than 18 years
  • Meets the diagnostic criteria for sepsis according to the "Sepsis-3"
  • Patient or their legal representative consents to treatment and signs an informed consent form

Who cannot take part

  • Contraindications to low molecular weight heparin and scopolamine butylbromide drugs
  • Patients with thrombotic diseases requiring treatment with low molecular weight heparin
  • Patients with terminal-stage malignancies, severe immunodeficiency, immunosuppression, severe liver or kidney dysfunction (defined as liver or kidney SOFA score ≥ 3 points), etc
  • Patients expected to die within 24 hours after enrollment
  • Pregnant and lactating women
  • Patients participating in other clinical trials

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Sepsis

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The study aimed to investigate the effectiveness of anisodamine hydrobromide combined with heparin in the treatment of patients with critical infection, in the hope that the therapy will provide alternatives to the treatment of patients with critical infection.

The 2 groups in the trial

  • Anisodamine hydrobromide combined with heparinTreatment being tested

    Anisodamine hydrobromide injection + low molecular weight heparin + basic treatment: The dosage of scopolamine butylbromide is 2.0mg/(kg\*d), administered via a micro-pump at a constant rate, continuously for 3 days. The dosage range for low molecular weight heparin is limited to 3000-6000U, administered subcutaneously once daily, continuously for 3 days.

  • conventional therapyNo study treatment, for comparison

    Conventional treatment includes shock treatment, eliminating the cause of the condition, actively treating the primary disease, replenishing blood volume, correcting acid-base imbalances, using vasoactive drugs to maintain blood pressure, and advanced life support as needed, such as the use of a ventilator and bedside blood filtration for organ support.

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Evaluation of the Efficacy of Anisodamine Hydrobromide Combined With Low-molecular-weight Heparin in the Treatment of Patients With Sepsis
Criteria questions
Built from NCT05634057, who can take part
Record updated
21 May 2025